Skip to content

In the BioHarmony Drug Report Database

Doxorubicin

Doxil (liposomal), Doxorubicin, Caelyx pegylated, Myocet (doxorubicin) is a small molecule pharmaceutical. Doxorubicin was first approved as Doxil (liposomal) on 1982-01-01. It is used to treat breast neoplasms, gastrointestinal neoplasms, hodgkin disease, lung neoplasms, and myeloid leukemia acute amongst others in the USA. It has been approved in Europe to treat breast neoplasms, kaposi sarcoma, multiple myeloma, and ovarian neoplasms. It is known to target DNA topoisomerase 2-alpha and sorcin.
Trade Name Caelyx pegylated liposomal, Myocet, Myocet liposomal
Common Name Doxorubicin
Indication breast neoplasms, gastrointestinal neoplasms, hodgkin disease, kaposi sarcoma, lung neoplasms, multiple myeloma, myeloid leukemia acute, neuroblastoma, osteosarcoma, ovarian neoplasms, precursor cell lymphoblastic leukemia-lymphoma, soft tissue neoplasms, thyroid neoplasms, urinary bladder neoplasms, wilms tumor
Drug Class Antineoplastic antibiotics (daunorubicin type)
Doxorubicin
Get full access now